Rheumatic Manifestations of Parkinson’s Disease: An Overview

Slouma, M.; Hajji, Haifa; Rahmouni, S.; Dhahri, R.; Métoui, L.; Gharsallah, I.

doi:10.2174/1573397119666230210162808

Cited by 3 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For many years, the disease may not produce any symptoms (2) . Diagnosis is sometimes troublesome because of the lack of pathognomonic symptoms and the wide variety of the disease (9) . Physicians' lack of awareness and understanding of Fabry disease causes them to diagnose other more common diseases, which include growth pain, Raynaud's syndrome, rheumatic pain, fibromyalgia or primary erythomelalgia (10).…”

Section: Symptomsmentioning

confidence: 99%

When should we think about Fabry disease?

Chojnacka,

Cymer,

Jurasz

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

According to the European Union definition, a rare disease is a disease that occurs with a frequency of less than 5 per 10,000. Rare diseases pose a major diagnostic problem for physicians. Due to the often uncharacteristic symptoms and rarity of the disease, it can take a long time before a correct diagnosis and treatment is made. Fabry disease is classified as a rare disease. It is an X-linked hereditary syndrome caused by alpha-galactosidase A deficiency. This leads to accumulation of glycosphingolipids in tissues and dysfunction of many organs. The clinical picture is variable and dependent on residual alpha-galactosidase A activity. The classic form of the disease occurs most often in males due to the presence of only one X chromosome. When alpha-galactosidase A activity is partially preserved, a non-classical form develops, which is more commonly seen in the female sex. The most common clinical manifestations reported by patients are angiokeratoma, anhidrosis, diarrhoea or left ventricular hypertrophy. To diagnose Fabry disease, alpha-galactosidase A activity can be measured in whole blood - dry blood drop test (DBS), plasma or leukocytes. Fabry disease can be treated effectively, but treatment must last for life. The treatments reimbursed in Poland are agalsidase alfa and beta preparations and migalastat.

show abstract

Section: Symptomsmentioning

confidence: 99%

When should we think about Fabry disease?

Chojnacka,

Cymer,

Jurasz

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Axial postural abnormalities (APAs) affect over 20% of individuals diagnosed with Parkinson's disease (PD), which significantly impairs their quality of life [1][2][3][4][5][6][7][8][9]. In addition, these abnormalities are closely associated with increased pain, a higher risk of falls, and reduced life quality [3,[10][11][12][13][14][15][16][17][18]. Axial symptoms are predominantly observed in the middle to advanced stages of PD and are characteristically resistant to conventional dopaminergic Toxins 2024, 16, 228 2 of 14 therapies [19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, these abnormalities are closely associated with increased pain, a higher risk of falls, and reduced life quality [3,[10][11][12][13][14][15][16][17][18]. Axial symptoms are predominantly observed in the middle to advanced stages of PD and are characteristically resistant to conventional dopaminergic Toxins 2024, 16, 228 2 of 14 therapies [19][20][21][22][23]. Recent advancements have led to a better understanding of their prevalence and classification.…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review

Gandolfi,

Artusi,

Imbalzano

et al. 2024

Toxins

View full text Add to dashboard Cite

Axial postural abnormalities (APAs), characterized by their frequency, disabling nature, and resistance to pharmacological treatments, significantly impact Parkinson’s disease and atypical Parkinsonism patients. Despite advancements in diagnosing, assessing, and understanding their pathophysiology, managing these complications remains a significant challenge. Often underestimated by healthcare professionals, these disturbances can exacerbate disability. This systematic review assesses botulinum toxin treatments’ effectiveness, alone and with rehabilitation, in addressing APAs in Parkinson’s disease, utilizing MEDLINE (PubMed), Web of Science, and SCOPUS databases for source material. Of the 1087 records retrieved, 16 met the selection criteria. Most research has focused on botulinum toxin (BoNT) as the primary treatment for camptocormia and Pisa syndrome, utilizing mostly observational methods. Despite dose and injection site variations, a common strategy was using electromyography-guided injections, occasionally enhanced with ultrasound. Patients with Pisa syndrome notably saw consistent improvements in APAs and pain. However, studies on the combined effects of botulinum toxin and rehabilitation are limited, and antecollis is significantly under-researched. These findings recommend precise BoNT injections into hyperactive muscles in well-selected patients by skilled clinicians, avoiding compensatory muscles, and underscore the necessity of early rehabilitation. Rehabilitation is crucial in a multidisciplinary approach to managing APAs, highlighting the importance of a multidisciplinary team of experts.

show abstract

Association between serum insulin-like growth factor 1 and osteoporosis risk in Parkinson's disease: a cross-sectional study

Geng,

Chen

2024

Neurol Sci

View full text Add to dashboard Cite

Rheumatic Manifestations of Parkinson’s Disease: An Overview

Cited by 3 publications

References 74 publications

When should we think about Fabry disease?

When should we think about Fabry disease?

Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review

Association between serum insulin-like growth factor 1 and osteoporosis risk in Parkinson's disease: a cross-sectional study

Contact Info

Product

Resources

About